These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30210333)

  • 61. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A potent new-scaffold androgen receptor antagonist discovered on the basis of a MIEC-SVM model.
    Wang XY; Chai X; Shan LH; Xu XH; Xu L; Hou TJ; Sun HY; Li D
    Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38750073
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated Through Molecular Dynamics Simulations.
    Sakkiah S; Kusko R; Pan B; Guo W; Ge W; Tong W; Hong H
    Front Pharmacol; 2018; 9():492. PubMed ID: 29867496
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthesis, biological evaluation, and molecular docking of novel hydroxyzine derivatives as potential AR antagonists.
    Qi Y; Xue B; Chen S; Wang W; Zhou H; Chen H
    Front Chem; 2022; 10():1053675. PubMed ID: 36405317
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nonsteroidal androgen receptor ligands: versatile syntheses and biological data.
    Varchi G; Guerrini A; Tesei A; Brigliadori G; Bertucci C; Di Donato M; Castoria G
    ACS Med Chem Lett; 2012 Jun; 3(6):454-8. PubMed ID: 24900495
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.
    Wang S; Ekoue DN; Raj GV; Kittler R
    Cancer Lett; 2018 Dec; 438():86-96. PubMed ID: 30217566
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5-
    Hammouda MM; Gaffer HE; Elattar KM
    RSC Med Chem; 2022 Oct; 13(10):1150-1196. PubMed ID: 36325400
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance.
    Tian X; He Y; Zhou J
    Front Pharmacol; 2015; 6():57. PubMed ID: 25852559
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists.
    Wang L; Song T; Wang X; Li J
    Front Pharmacol; 2018; 9():864. PubMed ID: 30210333
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
    Liu H; Han R; Li J; Liu H; Zheng L
    J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
    Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
    J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical relevance of androgen receptor alterations in prostate cancer.
    Jernberg E; Bergh A; Wikström P
    Endocr Connect; 2017 Nov; 6(8):R146-R161. PubMed ID: 29030409
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.